{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5+-+Fluorouracil&page=2", "query": { "intervention": "5 - Fluorouracil", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1156, "total_pages": 116, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5+-+Fluorouracil&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5+-+Fluorouracil&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T21:29:06.685Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01896531", "title": "A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2013-08-14", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 3, "location_summary": "Los Angeles, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896531" }, { "nct_id": "NCT01966471", "title": "A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1846, "start_date": "2014-01-31", "completion_date": "2021-06-04", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 50, "location_summary": "Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01966471" }, { "nct_id": "NCT01206530", "title": "FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer", "Colon Cancer", "Metastasis", "Adenocarcinoma" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-09", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01206530" }, { "nct_id": "NCT00055601", "title": "Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radical cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 97, "start_date": "2002-12", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 2, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055601" }, { "nct_id": "NCT00177307", "title": "Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-01", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2016-07-12", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00177307" }, { "nct_id": "NCT06598007", "title": "A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "CT3001", "type": "DRUG" }, { "name": "FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crossignal Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2024-09-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06598007" }, { "nct_id": "NCT04991948", "title": "Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unresectable Metastatic Colorectal Cancer" ], "interventions": [ { "name": "CYAD-101", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celyad Oncology SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-11-22", "completion_date": "2038-05-25", "has_results": false, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Tampa, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04991948" }, { "nct_id": "NCT03504397", "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma" ], "interventions": [ { "name": "zolbetuximab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "folinic acid", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 565, "start_date": "2018-06-21", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 51, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504397" }, { "nct_id": "NCT06764940", "title": "A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-negative Breast Cancer Patients With Brain Metastases" ], "interventions": [ { "name": "Utidelone", "type": "DRUG" }, { "name": "Utidelone in combination with capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biostar Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-07-14", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06764940" }, { "nct_id": "NCT01490866", "title": "A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-10-01T21:29:06.685Z", "location_count": 12, "location_summary": "Jonesboro, Arkansas • Fort Myers, Florida • Pensacola, Florida + 9 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490866" } ] }